These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 12966738)

  • 1. Should aromatase inhibitors replace tamoxifen?
    Drug Ther Bull; 2003 Aug; 41(8):57-9. PubMed ID: 12966738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of aromatase inhibitors in the treatment of metastatic breast cancer.
    Mouridsen H; Gershanovich M
    Semin Oncol; 2003 Aug; 30(4 Suppl 14):33-45. PubMed ID: 14513435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anastrozole.
    Cuzick J
    Drugs Today (Barc); 2005 Apr; 41(4):227-39. PubMed ID: 16034487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A roundtable discussion of aromatase inhibitors as therapy for breast cancer.
    Allred DC; Baum M; Buzdar AU; Carlson RW; Dowsett M; Elledge RM; Gradishar WJ; Grana G; Howell A; Mamounas EP
    Breast J; 2003; 9(3):213-22. PubMed ID: 12752630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging role of aromatase inhibitors in the adjuvant setting.
    Goss PE
    Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
    van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of anti-aromatase agents in postmenopausal advanced breast cancer.
    Murray R
    Cancer Chemother Pharmacol; 2001 Oct; 48(4):259-65. PubMed ID: 11710624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
    Aapro MS; Forbes JF
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A summary of second-line randomized studies of aromatase inhibitors.
    Buzdar AU
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):109-14. PubMed ID: 11850214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study].
    Gori S; Anastasi P; Marrocolo F
    Suppl Tumori; 2004; 3(4):S27-31. PubMed ID: 15206206
    [No Abstract]   [Full Text] [Related]  

  • 14. Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
    Sainsbury R
    Br J Cancer; 2004 May; 90(9):1733-9. PubMed ID: 15150604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal therapy in early and advanced breast cancer.
    Buzdar AU
    Breast J; 2004; 10 Suppl 1():S19-21. PubMed ID: 14984485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tamoxifen vs the aromatase inhibitors: news from San Antonio, 2001.
    Munster PN; Horton J
    Cancer Control; 2001; 8(6):478-9. PubMed ID: 11807416
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
    Dranitsaris G; Verma S; Trudeau M
    Am J Clin Oncol; 2003 Jun; 26(3):289-96. PubMed ID: 12796603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
    Nabholtz JM
    Am J Hosp Palliat Care; 2004; 21(6):457-65. PubMed ID: 15612238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
    Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.